Drugs to Fight Obesity and Type 2 Diabetes
Obesity
                    and diabetes are strongly linked. Obesity heightens
                    the risk of type 2 diabetes. In fact, 
                    according to The Obesity Society, 'the single
                      best predictor of type 2 diabetes is
                    overweight or obesity.' Further, according to the
                    society, “Almost 90% of people living with type 2
                    diabetes are overweight or have obesity.” Therefore,
                    it is incumbent on us to find ways to reduce obesity
                    and, thus, the risk of type II diabetes. Identifying
                    treatment methods that target obesity as well as
                    type 2 diabetes is an important undertaking. 
                  
Among
                    treatment methods that address obesity and type 2
                    diabetes are medications that might be used in novel
                    ways for treatment approaches. One medication used
                    to treat type 2 diabetes is Dapaglialozin. The
                    medication was developed by Bristol-Myers Squibb,
                    and given FDA approval in January of 2014. 
                  
Exenatide
                    is another medication used to treat type 2 diabetes.
                    It is developed by Amylin Pharmaceuticals. It was
                    given FDA approval in 2005. One study has shown that
                    “Dapaglifloozin
                      + exenatide dual therapy produced sustain
                    reduction in body weight, prediabetes, and SBP
                    [systolic blood pressure] over 52 weeks…” So this
                    combination drug may be useful in treating obesity
                    and preventing type 2 diabetes.
                  
Another
                    medication that may be helpful in the treatment of
                    obesity and diabetes is lorcaserin. Lorcaserin was
                    given FDA approval in 2012. It was approved to treat
                    obesity. But the drug may be helpful in the
                    treatment of type 2 diabetes as well as obesity.
                    Researchers in one study concluded that “lorcaserin
                      may have beneficial effects on glycemic
                    control with or without weight loss.”
                  
So
                    drugs already in use may be used in combinations to
                    enhance the treatment of both diabetes and type 2
                    diabetes. Using existing drugs in combination or in
                    novel protocols may provide new pathways to the
                    reduction of obesity and type 2 diabetes. Obesity
                    medicine specialists should be at the forefront of
                    this approach to the treatment obesity and type 2
                    diabetes.
-------------------------------------------------------

Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home